TWC 2019 Tessa Brabander _ CLNICAL TRIALS SUPPORTING FDA/EMA APPROVAL OF LUTATHERA

TWC 2019 Tessa Brabander _ CLNICAL TRIALS SUPPORTING FDA/EMA APPROVAL OF LUTATHERA

by Tessa Brabander

Life & Natural Systems Medicine & Health MBGRMedical researchMBGR1Clinical trials
🎙 Tessa Brabander 👥 358 📅 March 1, 2019 ⏱ 18 min 👁 32 📄 expert opinion 🧭 2026-08-18
Available in: English (current) Français

Keywords

Lutatheraclinical trialsFDA approvalEMA approvalneuroendocrine tumors

Summary

In this presentation from the TWC 2019 conference, Tessa Brabander discusses the clinical trials that supported the FDA and EMA approval of Lutathera, a radiopharmaceutical used for the treatment of neuroendocrine tumors. She highlights key efficacy data, including progression-free survival and overall survival outcomes from pivotal trials. The speaker also addresses safety concerns, particularly nephrotoxicity, and the importance of amino acid protection during treatment. She shares her extensive experience with over 1000 treatments and discusses adverse effects observed with similar therapies. The talk includes a discussion on the need for standardized protocols and the potential for optimizing treatment without compromising safety. The presentation is technical and aimed at a professional audience, providing insights into the real-world application of Lutathera and the challenges faced in clinical practice.

126 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the clinical evidence behind Lutathera’s approval, including specific survival data and safety considerations. The speaker’s argumentation is based on her own clinical experience and references to trial results, though the transcript is fragmented and lacks detailed citations. The discussion on nephrotoxicity and the role of amino acid protection adds practical value for clinicians. However, the argumentation could be strengthened with more explicit references to published studies and comparative data.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is moderate; the speaker references clinical trials but does not provide specific study names or citations in the transcript. The title accurately reflects the content, focusing on clinical trials supporting regulatory approval. The quality of sources is not fully verifiable from the provided information, but the speaker’s expertise lends credibility. The presentation would benefit from clearer references to the pivotal trials (e.g., NETTER-1) and regulatory documents.

159 words

Title / Content Match

The title accurately reflects the content, which discusses clinical trials supporting the approval of Lutathera.

Quality & Reliability

6/10

The presentation is based on clinical trial data and personal experience, but the transcript is fragmented and lacks detailed references. The speaker is an expert in the field, but the content is not fully verifiable from the provided information.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • No specific sources cited in the transcript — The transcript does not mention any specific sources or references.

Concurring Sources

  • NETTER-1 trial publication — The trial results align with the survival data mentioned in the presentation.

Dissenting Sources

  • No discordant sources identified — The transcript does not mention any conflicting evidence.

Contribution & Novelties

The presentation offers a clinical perspective on the use of Lutathera, emphasizing real-world experience and safety considerations. It adds value by discussing the importance of nephroprotection and potential variations in treatment protocols. The speaker’s extensive experience provides practical insights not commonly found in published literature.

Pour aller plus loin :

  • NETTER-1 trial — Pivotal trial for Lutathera approval.
  • FDA approval information — Official FDA approval details.
  • EMA assessment report — European Medicines Agency evaluation.

74 words

Radar Profile

The radar profile shows moderate scores across all dimensions, with slightly higher technical level and reliability, reflecting the expert presentation but limited verifiable content.

Reliability 6/10